UA-93693832-1skip to primary navigationskip to content

AstraZeneca areas of interest

AstraZeneca therapeutic areas of interest

AstraZeneca are looking to collaborate with academic researchers who have insight, tools, technologies and access to resources distinct to their own in the following areas:

Cardiovascular and metabolic diseases

  • Cardiac Regeneration
  • Islet Cell Health (Diabetes)
  • Diabetic Nephropathy

Oncology

  • Genetic Drivers and Resistance Mechanisms
  • Immune-Mediated Therapies
  • DNA Damage Response
  • Antibody-Drug Conjugates

Respiratory, inflammation and autoimmunity                                  

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rheumatoid Arthritis (RA)
  • Systemic Lupus Erythematosus (SLE)

 

Technology and platform innovation

Neuroscience

  • Neurodegenerative diseases including:
  • Alzheimer’s disease
  • Parkinson’s disease
  • Frontotemporal dementia
  • Huntington’s disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Psychiatry
  • Autism spectrum disorders
  • Refractory major depressive disorder
  • Addiction disorder
  • Behavioral symptoms in dementia
  • Analgesia                                                          

What can AstraZeneca offer academic scientists?

AstraZeneca has created tools and technologies that are unique, of interest, and enabling to external investigators such as:

Compound Libraries

  • > 20 clinical ready compounds [List available click here]
  • > 40 mechanistic tool compounds [List available click here]
  • < 250,000 compounds for high throughput screening [for more information about accessing the library click here]

High throughput screening facilities

  • For more information on performing a HTS with AZ click here 

Cheminformatic and physical property/DMPK analysis of your compounds

  • Compound structures are shared via third party to ensure confidentiality [more information click here]                                  

250chemicals

Open innovation and a flexible approach to collaboration

Open innovation and collaboration is a central part of AstraZeneca’s R&D strategy. A comprehensive suite of open innovation partnership models are available see the figure below and click here. They include but are not limited to:

  • Access to compounds and screening libraries
  • Partnerships and collaborative research funding
  • Sabbaticals to work in AstraZeneca laboratories in Cambridge
  • Prizes for solutions through R&D challenges run through Innocentive [click here]

AstraZeneca has a vibrant, highly developed network of collaborations with academic scientists around the world including many in Cambridge and we are keen to establish more research collaborations with scientists in Cambridge through the Milner Therapeutics Consortium. An example is the collaboration between AstraZeneca and Prof Carlos Caldas at the University of Cambridge described here. These collaborations can be facilitated through match-making with individual scientists or meetings and workshops between groups of scientists working in relevant areas. For more information please contact Kathryn.Chapman@milner.cam.ac.uk

 

For more information on AstraZeneca click on the logo      175 logo astrazeneca T

                                                                                                                                                                                           

 

880 open innovation AZ

 

       

 

 

 

       

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

        See Affiliated Companies